Zacks Research Issues Pessimistic Outlook for JNJ Earnings

Johnson & Johnson (NYSE:JNJ - Free Report) - Zacks Research cut their Q1 2025 earnings per share estimates for Johnson & Johnson in a report issued on Wednesday, February 12th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $2.60 per share for the quarter, down from their prior forecast of $2.63. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q3 2025 earnings at $2.78 EPS, Q4 2025 earnings at $2.48 EPS, FY2025 earnings at $10.55 EPS, Q1 2026 earnings at $2.66 EPS, Q2 2026 earnings at $2.76 EPS, Q3 2026 earnings at $2.79 EPS, Q4 2026 earnings at $2.83 EPS and FY2027 earnings at $11.48 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the firm posted $2.29 EPS. The business's revenue was up 5.3% compared to the same quarter last year.

Other equities analysts also recently issued reports about the stock. Leerink Partners dropped their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a report on Thursday, January 23rd. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an "outperform" rating and a $190.00 price target for the company. Guggenheim boosted their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Stifel Nicolaus lowered their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a report on Thursday, January 23rd. Finally, Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $170.67.

Johnson & Johnson Price Performance

Shares of JNJ traded down $1.05 on Friday, reaching $156.20. The stock had a trading volume of 6,402,249 shares, compared to its average volume of 9,304,454. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The firm has a market capitalization of $376.08 billion, a PE ratio of 23.49, a PEG ratio of 2.46 and a beta of 0.52. The firm has a 50-day moving average of $147.87 and a 200 day moving average of $155.95. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of the stock. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $29,000. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $31,000. Finally, Bay Harbor Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $32,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.